Rapamycin and its analogues, termed rapalogues, act as allosteric inhibitors of mTOR; however, due to their incomplete mTORC1 inhibition or the loss of negative feedback loops resulting in unexpected mTORC2 activation, they have generally been ineffective in GBM clinical trials [53]. Here, MTOR is linked to glioblastoma.